Xiaoqing Liu

发表

Updated overall survival and circulating tumor DNA analysis of ensartinib for crizotinib‐refractory ALK‐positive NSCLC from a phase II study

W. Feng, K. Ma, G. Selvaggi, 2024, Cancer communications.